Global Next-Generation Breast Cancer Diagnostic and Screening Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Next-Generation Breast Cancer Diagnostic and Screening market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Next-Generation Breast Cancer Diagnostic and Screening market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Next-Generation Breast Cancer Diagnostic and Screening market size and forecasts, in consumption value ($ Million), 2018-2029
Global Next-Generation Breast Cancer Diagnostic and Screening market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Next-Generation Breast Cancer Diagnostic and Screening market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Next-Generation Breast Cancer Diagnostic and Screening market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Next-Generation Breast Cancer Diagnostic and Screening
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Next-Generation Breast Cancer Diagnostic and Screening market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics and Biocept, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Next-Generation Breast Cancer Diagnostic and Screening market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Next-Generation Breast Cancer Diagnostic and Screening product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Next-Generation Breast Cancer Diagnostic and Screening, with revenue, gross margin and global market share of Next-Generation Breast Cancer Diagnostic and Screening from 2018 to 2023.
Chapter 3, the Next-Generation Breast Cancer Diagnostic and Screening competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Next-Generation Breast Cancer Diagnostic and Screening market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Next-Generation Breast Cancer Diagnostic and Screening.
Chapter 13, to describe Next-Generation Breast Cancer Diagnostic and Screening research findings and conclusion.
This report is a detailed and comprehensive analysis for global Next-Generation Breast Cancer Diagnostic and Screening market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Next-Generation Breast Cancer Diagnostic and Screening market size and forecasts, in consumption value ($ Million), 2018-2029
Global Next-Generation Breast Cancer Diagnostic and Screening market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Next-Generation Breast Cancer Diagnostic and Screening market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Next-Generation Breast Cancer Diagnostic and Screening market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Next-Generation Breast Cancer Diagnostic and Screening
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Next-Generation Breast Cancer Diagnostic and Screening market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics and Biocept, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Next-Generation Breast Cancer Diagnostic and Screening market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Real-Time PCR (q-PCR)
- Immunohistochemistry (IHC)
- Next-Generation Sequencing (NGS)
- Fluorescent In-Situ Hybridization (FISH)
- Hospital-associated Labs
- Cancer Research Institutes
- Diagnostic Centers
- Abbott Laboratories
- Agendia
- Agilent Technologies
- Ambry Genetics
- Biocept
- Biotheranostics
- Centogene
- Danaher Corporation
- EXACT Sciences Corporation
- Roche Holding AG
- Fulgent Genetics
- Illumina
- Invitae
- Lucence Diagnostics Pte Ltd
- Myriad Genetics
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Next-Generation Breast Cancer Diagnostic and Screening product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Next-Generation Breast Cancer Diagnostic and Screening, with revenue, gross margin and global market share of Next-Generation Breast Cancer Diagnostic and Screening from 2018 to 2023.
Chapter 3, the Next-Generation Breast Cancer Diagnostic and Screening competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Next-Generation Breast Cancer Diagnostic and Screening market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Next-Generation Breast Cancer Diagnostic and Screening.
Chapter 13, to describe Next-Generation Breast Cancer Diagnostic and Screening research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Next-Generation Breast Cancer Diagnostic and Screening
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Next-Generation Breast Cancer Diagnostic and Screening by Type
1.3.1 Overview: Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type in 2022
1.3.3 Real-Time PCR (q-PCR)
1.3.4 Immunohistochemistry (IHC)
1.3.5 Next-Generation Sequencing (NGS)
1.3.6 Fluorescent In-Situ Hybridization (FISH)
1.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Application
1.4.1 Overview: Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital-associated Labs
1.4.3 Cancer Research Institutes
1.4.4 Diagnostic Centers
1.5 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size & Forecast
1.6 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast by Region
1.6.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region, (2018-2029)
1.6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2018-2029)
1.6.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2018-2029)
1.6.6 South America Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business
2.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.1.4 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Abbott Laboratories Recent Developments and Future Plans
2.2 Agendia
2.2.1 Agendia Details
2.2.2 Agendia Major Business
2.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.2.4 Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Agendia Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.3.4 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 Ambry Genetics
2.4.1 Ambry Genetics Details
2.4.2 Ambry Genetics Major Business
2.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.4.4 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Ambry Genetics Recent Developments and Future Plans
2.5 Biocept
2.5.1 Biocept Details
2.5.2 Biocept Major Business
2.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.5.4 Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Biocept Recent Developments and Future Plans
2.6 Biotheranostics
2.6.1 Biotheranostics Details
2.6.2 Biotheranostics Major Business
2.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.6.4 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Biotheranostics Recent Developments and Future Plans
2.7 Centogene
2.7.1 Centogene Details
2.7.2 Centogene Major Business
2.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.7.4 Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Centogene Recent Developments and Future Plans
2.8 Danaher Corporation
2.8.1 Danaher Corporation Details
2.8.2 Danaher Corporation Major Business
2.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.8.4 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Danaher Corporation Recent Developments and Future Plans
2.9 EXACT Sciences Corporation
2.9.1 EXACT Sciences Corporation Details
2.9.2 EXACT Sciences Corporation Major Business
2.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.9.4 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 EXACT Sciences Corporation Recent Developments and Future Plans
2.10 Roche Holding AG
2.10.1 Roche Holding AG Details
2.10.2 Roche Holding AG Major Business
2.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.10.4 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Roche Holding AG Recent Developments and Future Plans
2.11 Fulgent Genetics
2.11.1 Fulgent Genetics Details
2.11.2 Fulgent Genetics Major Business
2.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.11.4 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Fulgent Genetics Recent Developments and Future Plans
2.12 Illumina
2.12.1 Illumina Details
2.12.2 Illumina Major Business
2.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.12.4 Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Illumina Recent Developments and Future Plans
2.13 Invitae
2.13.1 Invitae Details
2.13.2 Invitae Major Business
2.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.13.4 Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Invitae Recent Developments and Future Plans
2.14 Lucence Diagnostics Pte Ltd
2.14.1 Lucence Diagnostics Pte Ltd Details
2.14.2 Lucence Diagnostics Pte Ltd Major Business
2.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.14.4 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Lucence Diagnostics Pte Ltd Recent Developments and Future Plans
2.15 Myriad Genetics
2.15.1 Myriad Genetics Details
2.15.2 Myriad Genetics Major Business
2.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.15.4 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Myriad Genetics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Next-Generation Breast Cancer Diagnostic and Screening by Company Revenue
3.2.2 Top 3 Next-Generation Breast Cancer Diagnostic and Screening Players Market Share in 2022
3.2.3 Top 6 Next-Generation Breast Cancer Diagnostic and Screening Players Market Share in 2022
3.3 Next-Generation Breast Cancer Diagnostic and Screening Market: Overall Company Footprint Analysis
3.3.1 Next-Generation Breast Cancer Diagnostic and Screening Market: Region Footprint
3.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market: Company Product Type Footprint
3.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value and Market Share by Type (2018-2023)
4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2023)
5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2029)
6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2029)
6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
6.3.1 North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2029)
6.3.2 United States Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
6.3.3 Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
6.3.4 Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2029)
7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2029)
7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
7.3.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2029)
7.3.2 Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
7.3.3 France Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
7.3.5 Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
7.3.6 Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region
8.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Region (2018-2029)
8.3.2 China Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8.3.3 Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8.3.4 South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8.3.5 India Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8.3.7 Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2029)
9.2 South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2029)
9.3 South America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
9.3.1 South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2029)
9.3.2 Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
9.3.3 Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
10.3.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2029)
10.3.2 Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
10.3.4 UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
11.2 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
11.3 Next-Generation Breast Cancer Diagnostic and Screening Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Next-Generation Breast Cancer Diagnostic and Screening Industry Chain
12.2 Next-Generation Breast Cancer Diagnostic and Screening Upstream Analysis
12.3 Next-Generation Breast Cancer Diagnostic and Screening Midstream Analysis
12.4 Next-Generation Breast Cancer Diagnostic and Screening Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Next-Generation Breast Cancer Diagnostic and Screening
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Next-Generation Breast Cancer Diagnostic and Screening by Type
1.3.1 Overview: Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type in 2022
1.3.3 Real-Time PCR (q-PCR)
1.3.4 Immunohistochemistry (IHC)
1.3.5 Next-Generation Sequencing (NGS)
1.3.6 Fluorescent In-Situ Hybridization (FISH)
1.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Application
1.4.1 Overview: Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital-associated Labs
1.4.3 Cancer Research Institutes
1.4.4 Diagnostic Centers
1.5 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size & Forecast
1.6 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast by Region
1.6.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region, (2018-2029)
1.6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2018-2029)
1.6.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2018-2029)
1.6.6 South America Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business
2.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.1.4 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Abbott Laboratories Recent Developments and Future Plans
2.2 Agendia
2.2.1 Agendia Details
2.2.2 Agendia Major Business
2.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.2.4 Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Agendia Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.3.4 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 Ambry Genetics
2.4.1 Ambry Genetics Details
2.4.2 Ambry Genetics Major Business
2.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.4.4 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Ambry Genetics Recent Developments and Future Plans
2.5 Biocept
2.5.1 Biocept Details
2.5.2 Biocept Major Business
2.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.5.4 Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Biocept Recent Developments and Future Plans
2.6 Biotheranostics
2.6.1 Biotheranostics Details
2.6.2 Biotheranostics Major Business
2.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.6.4 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Biotheranostics Recent Developments and Future Plans
2.7 Centogene
2.7.1 Centogene Details
2.7.2 Centogene Major Business
2.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.7.4 Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Centogene Recent Developments and Future Plans
2.8 Danaher Corporation
2.8.1 Danaher Corporation Details
2.8.2 Danaher Corporation Major Business
2.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.8.4 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Danaher Corporation Recent Developments and Future Plans
2.9 EXACT Sciences Corporation
2.9.1 EXACT Sciences Corporation Details
2.9.2 EXACT Sciences Corporation Major Business
2.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.9.4 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 EXACT Sciences Corporation Recent Developments and Future Plans
2.10 Roche Holding AG
2.10.1 Roche Holding AG Details
2.10.2 Roche Holding AG Major Business
2.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.10.4 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Roche Holding AG Recent Developments and Future Plans
2.11 Fulgent Genetics
2.11.1 Fulgent Genetics Details
2.11.2 Fulgent Genetics Major Business
2.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.11.4 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Fulgent Genetics Recent Developments and Future Plans
2.12 Illumina
2.12.1 Illumina Details
2.12.2 Illumina Major Business
2.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.12.4 Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Illumina Recent Developments and Future Plans
2.13 Invitae
2.13.1 Invitae Details
2.13.2 Invitae Major Business
2.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.13.4 Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Invitae Recent Developments and Future Plans
2.14 Lucence Diagnostics Pte Ltd
2.14.1 Lucence Diagnostics Pte Ltd Details
2.14.2 Lucence Diagnostics Pte Ltd Major Business
2.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.14.4 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Lucence Diagnostics Pte Ltd Recent Developments and Future Plans
2.15 Myriad Genetics
2.15.1 Myriad Genetics Details
2.15.2 Myriad Genetics Major Business
2.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.15.4 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Myriad Genetics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Next-Generation Breast Cancer Diagnostic and Screening by Company Revenue
3.2.2 Top 3 Next-Generation Breast Cancer Diagnostic and Screening Players Market Share in 2022
3.2.3 Top 6 Next-Generation Breast Cancer Diagnostic and Screening Players Market Share in 2022
3.3 Next-Generation Breast Cancer Diagnostic and Screening Market: Overall Company Footprint Analysis
3.3.1 Next-Generation Breast Cancer Diagnostic and Screening Market: Region Footprint
3.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market: Company Product Type Footprint
3.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value and Market Share by Type (2018-2023)
4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2023)
5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2029)
6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2029)
6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
6.3.1 North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2029)
6.3.2 United States Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
6.3.3 Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
6.3.4 Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2029)
7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2029)
7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
7.3.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2029)
7.3.2 Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
7.3.3 France Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
7.3.5 Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
7.3.6 Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region
8.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Region (2018-2029)
8.3.2 China Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8.3.3 Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8.3.4 South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8.3.5 India Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
8.3.7 Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2029)
9.2 South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2029)
9.3 South America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
9.3.1 South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2029)
9.3.2 Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
9.3.3 Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
10.3.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2029)
10.3.2 Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
10.3.4 UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
11.2 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
11.3 Next-Generation Breast Cancer Diagnostic and Screening Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Next-Generation Breast Cancer Diagnostic and Screening Industry Chain
12.2 Next-Generation Breast Cancer Diagnostic and Screening Upstream Analysis
12.3 Next-Generation Breast Cancer Diagnostic and Screening Midstream Analysis
12.4 Next-Generation Breast Cancer Diagnostic and Screening Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Abbott Laboratories Company Information, Head Office, and Major Competitors
Table 6. Abbott Laboratories Major Business
Table 7. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 8. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Abbott Laboratories Recent Developments and Future Plans
Table 10. Agendia Company Information, Head Office, and Major Competitors
Table 11. Agendia Major Business
Table 12. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 13. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Agendia Recent Developments and Future Plans
Table 15. Agilent Technologies Company Information, Head Office, and Major Competitors
Table 16. Agilent Technologies Major Business
Table 17. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 18. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Agilent Technologies Recent Developments and Future Plans
Table 20. Ambry Genetics Company Information, Head Office, and Major Competitors
Table 21. Ambry Genetics Major Business
Table 22. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 23. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Ambry Genetics Recent Developments and Future Plans
Table 25. Biocept Company Information, Head Office, and Major Competitors
Table 26. Biocept Major Business
Table 27. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 28. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Biocept Recent Developments and Future Plans
Table 30. Biotheranostics Company Information, Head Office, and Major Competitors
Table 31. Biotheranostics Major Business
Table 32. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 33. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Biotheranostics Recent Developments and Future Plans
Table 35. Centogene Company Information, Head Office, and Major Competitors
Table 36. Centogene Major Business
Table 37. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 38. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Centogene Recent Developments and Future Plans
Table 40. Danaher Corporation Company Information, Head Office, and Major Competitors
Table 41. Danaher Corporation Major Business
Table 42. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 43. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Danaher Corporation Recent Developments and Future Plans
Table 45. EXACT Sciences Corporation Company Information, Head Office, and Major Competitors
Table 46. EXACT Sciences Corporation Major Business
Table 47. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 48. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. EXACT Sciences Corporation Recent Developments and Future Plans
Table 50. Roche Holding AG Company Information, Head Office, and Major Competitors
Table 51. Roche Holding AG Major Business
Table 52. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 53. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Roche Holding AG Recent Developments and Future Plans
Table 55. Fulgent Genetics Company Information, Head Office, and Major Competitors
Table 56. Fulgent Genetics Major Business
Table 57. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 58. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Fulgent Genetics Recent Developments and Future Plans
Table 60. Illumina Company Information, Head Office, and Major Competitors
Table 61. Illumina Major Business
Table 62. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 63. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Illumina Recent Developments and Future Plans
Table 65. Invitae Company Information, Head Office, and Major Competitors
Table 66. Invitae Major Business
Table 67. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 68. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Invitae Recent Developments and Future Plans
Table 70. Lucence Diagnostics Pte Ltd Company Information, Head Office, and Major Competitors
Table 71. Lucence Diagnostics Pte Ltd Major Business
Table 72. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 73. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Lucence Diagnostics Pte Ltd Recent Developments and Future Plans
Table 75. Myriad Genetics Company Information, Head Office, and Major Competitors
Table 76. Myriad Genetics Major Business
Table 77. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 78. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Myriad Genetics Recent Developments and Future Plans
Table 80. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) by Players (2018-2023)
Table 81. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Players (2018-2023)
Table 82. Breakdown of Next-Generation Breast Cancer Diagnostic and Screening by Company Type (Tier 1, Tier 2, and Tier 3)
Table 83. Market Position of Players in Next-Generation Breast Cancer Diagnostic and Screening, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 84. Head Office of Key Next-Generation Breast Cancer Diagnostic and Screening Players
Table 85. Next-Generation Breast Cancer Diagnostic and Screening Market: Company Product Type Footprint
Table 86. Next-Generation Breast Cancer Diagnostic and Screening Market: Company Product Application Footprint
Table 87. Next-Generation Breast Cancer Diagnostic and Screening New Market Entrants and Barriers to Market Entry
Table 88. Next-Generation Breast Cancer Diagnostic and Screening Mergers, Acquisition, Agreements, and Collaborations
Table 89. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (USD Million) by Type (2018-2023)
Table 90. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Share by Type (2018-2023)
Table 91. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Forecast by Type (2024-2029)
Table 92. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023)
Table 93. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Forecast by Application (2024-2029)
Table 94. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2023) & (USD Million)
Table 95. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2024-2029) & (USD Million)
Table 96. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023) & (USD Million)
Table 97. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2024-2029) & (USD Million)
Table 98. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2023) & (USD Million)
Table 99. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2024-2029) & (USD Million)
Table 100. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2023) & (USD Million)
Table 101. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2024-2029) & (USD Million)
Table 102. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023) & (USD Million)
Table 103. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2024-2029) & (USD Million)
Table 104. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2023) & (USD Million)
Table 107. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2024-2029) & (USD Million)
Table 108. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023) & (USD Million)
Table 109. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2024-2029) & (USD Million)
Table 110. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Region (2018-2023) & (USD Million)
Table 111. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Region (2024-2029) & (USD Million)
Table 112. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2023) & (USD Million)
Table 113. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2024-2029) & (USD Million)
Table 114. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023) & (USD Million)
Table 115. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2024-2029) & (USD Million)
Table 116. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2023) & (USD Million)
Table 117. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2024-2029) & (USD Million)
Table 118. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2023) & (USD Million)
Table 119. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2024-2029) & (USD Million)
Table 120. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023) & (USD Million)
Table 121. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2024-2029) & (USD Million)
Table 122. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2023) & (USD Million)
Table 123. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2024-2029) & (USD Million)
Table 124. Next-Generation Breast Cancer Diagnostic and Screening Raw Material
Table 125. Key Suppliers of Next-Generation Breast Cancer Diagnostic and Screening Raw Materials
Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Abbott Laboratories Company Information, Head Office, and Major Competitors
Table 6. Abbott Laboratories Major Business
Table 7. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 8. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Abbott Laboratories Recent Developments and Future Plans
Table 10. Agendia Company Information, Head Office, and Major Competitors
Table 11. Agendia Major Business
Table 12. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 13. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Agendia Recent Developments and Future Plans
Table 15. Agilent Technologies Company Information, Head Office, and Major Competitors
Table 16. Agilent Technologies Major Business
Table 17. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 18. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Agilent Technologies Recent Developments and Future Plans
Table 20. Ambry Genetics Company Information, Head Office, and Major Competitors
Table 21. Ambry Genetics Major Business
Table 22. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 23. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Ambry Genetics Recent Developments and Future Plans
Table 25. Biocept Company Information, Head Office, and Major Competitors
Table 26. Biocept Major Business
Table 27. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 28. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Biocept Recent Developments and Future Plans
Table 30. Biotheranostics Company Information, Head Office, and Major Competitors
Table 31. Biotheranostics Major Business
Table 32. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 33. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Biotheranostics Recent Developments and Future Plans
Table 35. Centogene Company Information, Head Office, and Major Competitors
Table 36. Centogene Major Business
Table 37. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 38. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Centogene Recent Developments and Future Plans
Table 40. Danaher Corporation Company Information, Head Office, and Major Competitors
Table 41. Danaher Corporation Major Business
Table 42. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 43. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Danaher Corporation Recent Developments and Future Plans
Table 45. EXACT Sciences Corporation Company Information, Head Office, and Major Competitors
Table 46. EXACT Sciences Corporation Major Business
Table 47. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 48. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. EXACT Sciences Corporation Recent Developments and Future Plans
Table 50. Roche Holding AG Company Information, Head Office, and Major Competitors
Table 51. Roche Holding AG Major Business
Table 52. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 53. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Roche Holding AG Recent Developments and Future Plans
Table 55. Fulgent Genetics Company Information, Head Office, and Major Competitors
Table 56. Fulgent Genetics Major Business
Table 57. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 58. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Fulgent Genetics Recent Developments and Future Plans
Table 60. Illumina Company Information, Head Office, and Major Competitors
Table 61. Illumina Major Business
Table 62. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 63. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Illumina Recent Developments and Future Plans
Table 65. Invitae Company Information, Head Office, and Major Competitors
Table 66. Invitae Major Business
Table 67. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 68. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Invitae Recent Developments and Future Plans
Table 70. Lucence Diagnostics Pte Ltd Company Information, Head Office, and Major Competitors
Table 71. Lucence Diagnostics Pte Ltd Major Business
Table 72. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 73. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Lucence Diagnostics Pte Ltd Recent Developments and Future Plans
Table 75. Myriad Genetics Company Information, Head Office, and Major Competitors
Table 76. Myriad Genetics Major Business
Table 77. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 78. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Myriad Genetics Recent Developments and Future Plans
Table 80. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) by Players (2018-2023)
Table 81. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Players (2018-2023)
Table 82. Breakdown of Next-Generation Breast Cancer Diagnostic and Screening by Company Type (Tier 1, Tier 2, and Tier 3)
Table 83. Market Position of Players in Next-Generation Breast Cancer Diagnostic and Screening, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 84. Head Office of Key Next-Generation Breast Cancer Diagnostic and Screening Players
Table 85. Next-Generation Breast Cancer Diagnostic and Screening Market: Company Product Type Footprint
Table 86. Next-Generation Breast Cancer Diagnostic and Screening Market: Company Product Application Footprint
Table 87. Next-Generation Breast Cancer Diagnostic and Screening New Market Entrants and Barriers to Market Entry
Table 88. Next-Generation Breast Cancer Diagnostic and Screening Mergers, Acquisition, Agreements, and Collaborations
Table 89. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (USD Million) by Type (2018-2023)
Table 90. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Share by Type (2018-2023)
Table 91. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Forecast by Type (2024-2029)
Table 92. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023)
Table 93. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Forecast by Application (2024-2029)
Table 94. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2023) & (USD Million)
Table 95. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2024-2029) & (USD Million)
Table 96. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023) & (USD Million)
Table 97. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2024-2029) & (USD Million)
Table 98. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2023) & (USD Million)
Table 99. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2024-2029) & (USD Million)
Table 100. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2023) & (USD Million)
Table 101. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2024-2029) & (USD Million)
Table 102. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023) & (USD Million)
Table 103. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2024-2029) & (USD Million)
Table 104. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2023) & (USD Million)
Table 107. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2024-2029) & (USD Million)
Table 108. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023) & (USD Million)
Table 109. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2024-2029) & (USD Million)
Table 110. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Region (2018-2023) & (USD Million)
Table 111. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Region (2024-2029) & (USD Million)
Table 112. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2023) & (USD Million)
Table 113. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2024-2029) & (USD Million)
Table 114. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023) & (USD Million)
Table 115. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2024-2029) & (USD Million)
Table 116. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2023) & (USD Million)
Table 117. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2024-2029) & (USD Million)
Table 118. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2018-2023) & (USD Million)
Table 119. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type (2024-2029) & (USD Million)
Table 120. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2018-2023) & (USD Million)
Table 121. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Application (2024-2029) & (USD Million)
Table 122. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2018-2023) & (USD Million)
Table 123. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Country (2024-2029) & (USD Million)
Table 124. Next-Generation Breast Cancer Diagnostic and Screening Raw Material
Table 125. Key Suppliers of Next-Generation Breast Cancer Diagnostic and Screening Raw Materials
LIST OF FIGURES
Figure 1. Next-Generation Breast Cancer Diagnostic and Screening Picture
Figure 2. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type in 2022
Figure 4. Real-Time PCR (q-PCR)
Figure 5. Immunohistochemistry (IHC)
Figure 6. Next-Generation Sequencing (NGS)
Figure 7. Fluorescent In-Situ Hybridization (FISH)
Figure 8. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application in 2022
Figure 10. Hospital-associated Labs Picture
Figure 11. Cancer Research Institutes Picture
Figure 12. Diagnostic Centers Picture
Figure 13. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Region in 2022
Figure 18. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Players in 2022
Figure 24. Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Next-Generation Breast Cancer Diagnostic and Screening Market Share in 2022
Figure 26. Global Top 6 Players Next-Generation Breast Cancer Diagnostic and Screening Market Share in 2022
Figure 27. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Share by Type (2018-2023)
Figure 28. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share Forecast by Type (2024-2029)
Figure 29. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Share by Application (2018-2023)
Figure 30. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share Forecast by Application (2024-2029)
Figure 31. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 41. France Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Region (2018-2029)
Figure 48. China Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 51. India Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 65. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
Figure 66. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
Figure 67. Next-Generation Breast Cancer Diagnostic and Screening Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Next-Generation Breast Cancer Diagnostic and Screening in 2022
Figure 70. Manufacturing Process Analysis of Next-Generation Breast Cancer Diagnostic and Screening
Figure 71. Next-Generation Breast Cancer Diagnostic and Screening Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. Next-Generation Breast Cancer Diagnostic and Screening Picture
Figure 2. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type in 2022
Figure 4. Real-Time PCR (q-PCR)
Figure 5. Immunohistochemistry (IHC)
Figure 6. Next-Generation Sequencing (NGS)
Figure 7. Fluorescent In-Situ Hybridization (FISH)
Figure 8. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application in 2022
Figure 10. Hospital-associated Labs Picture
Figure 11. Cancer Research Institutes Picture
Figure 12. Diagnostic Centers Picture
Figure 13. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Region in 2022
Figure 18. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Players in 2022
Figure 24. Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Next-Generation Breast Cancer Diagnostic and Screening Market Share in 2022
Figure 26. Global Top 6 Players Next-Generation Breast Cancer Diagnostic and Screening Market Share in 2022
Figure 27. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Share by Type (2018-2023)
Figure 28. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share Forecast by Type (2024-2029)
Figure 29. Global Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Share by Application (2018-2023)
Figure 30. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share Forecast by Application (2024-2029)
Figure 31. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 41. France Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Region (2018-2029)
Figure 48. China Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 51. India Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Next-Generation Breast Cancer Diagnostic and Screening Consumption Value (2018-2029) & (USD Million)
Figure 65. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
Figure 66. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
Figure 67. Next-Generation Breast Cancer Diagnostic and Screening Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Next-Generation Breast Cancer Diagnostic and Screening in 2022
Figure 70. Manufacturing Process Analysis of Next-Generation Breast Cancer Diagnostic and Screening
Figure 71. Next-Generation Breast Cancer Diagnostic and Screening Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
